HP
ALDX icon

HealthInvest Partners’s Aldeyra Therapeutics ALDX Stock Holding History

HealthInvest Partners’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-310,000
Closed -$2.72M – 14
2021
Q3 		$2.72M Buy
+310,000
New +$2.85M 4.08% 9

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

HealthInvest Partners's ALDX Position: Q4 2021 in Review

HealthInvest Partners sold out of Aldeyra Therapeutics (ALDX) in Q4 2021, closing a stake of 310,000 shares — an estimated $2.72M sold.

HealthInvest Partners first reported a position in ALDX in Q3 2021 and held it in 1 quarter. The position peaked at $2.72M in Q3 2021. 115 funds tracked by Wall St. Rank hold ALDX as of Q4 2021.

  • HealthInvest Partners reported no remaining Aldeyra Therapeutics position as of Q4 2021 after selling out during the quarter.
  • HealthInvest Partners sold 310,000 Aldeyra Therapeutics shares in Q4 2021, an estimated $2.72M.
  • HealthInvest Partners first reported a position in Aldeyra Therapeutics in Q3 2021 and held it in 1 quarter.
  • HealthInvest Partners's Aldeyra Therapeutics position peaked at $2.72M in Q3 2021.
  • 115 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2021.

Based on HealthInvest Partners's 13F filing for Q4 2021, filed 18 Jan 2022.